Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: Evaluation of safety and immunogenicity

Vaccine

Volumn 22, Issue 2, 2003, Pages 217-223

  Ehrlich, Hartmut J ^a   Pavlova, Borislava G ^a   Fritsch, Sandor ^a   Poellabauer, Eva Maria ^a   Loew Baselli, Alexandra ^a   Obermann Slupetzky, Ortrun ^a   Maritsch, Friedrich ^a   Cil, Ingeborg ^a   Dorner, Friedrich ^a   Barrett, P Noel ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Dose finding; Modified FSME IMMUN vaccine; Tick borne encephalitis

Indexed keywords

FSME IMMUN; IMMUNOGLOBULIN G ANTIBODY; TICK BORNE ENCEPHALITIS VACCINE;

ADOLESCENT; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MALE; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SERODIAGNOSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TICK BORNE ENCEPHALITIS; TREATMENT OUTCOME; VACCINATION;

EID: 10744232162     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00563-2     Document Type: Article

References (11)

1. Monath TP, Heinz FX. Flaviviruses. In: Fields BN, Knipe DM, Howly PM, editors. Fields virology. 3rd ed. Philadelphia: Raven; 1996. p. 961-1034.
2. Krausler J., Kraus P., Moritsch H. Klinische und virologisch- serologische Untersuchungsergebnisse bei Frühsommer-Meningoencephalitis und anderen Virusinfektionen des ZNS im Bezirk Neunkirchen. Wien Klin Wochenschr. 70:1958;634-637.
3. Radda A. Die Frühsommer-Meningoenzephalitis in Österreich. In: Jusatz H, editor. Beiträge zur Geoökologie der Zentraleuropä ischen Zecken-Encephalitis. Berlin: Springer-Verlag; 1978. p. 42-7.
4. Barrett P.N., Schober-Bendixen S., Ehrlich H. History of TBE vaccines. Vaccine. 21(Suppl. 1):2003;41-49.
5. Marth E., Kleinhappl B. Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. Vaccine. 20:2002;532-537.
6. Holzmann H., Kundi M., Stiasny K., Clement J., McKenna P., Kunz C.et al. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. J. Med. Virol. 48:1996;102-107.
7. Cancer Therapy Evaluation Program, Common Toxicity Criteria, Version 2.0, 1999 April 30.
8. Agresti A. Estimating proportions and relative risk. In: Categorical data analysis. New York: Wiley; 1990. p. 55.
9. Guiliano K.K., Guiliano A.J., Scott S.S., MacLachlan E., Pysznik E., Elliot S.et al. Temperature measurement in critically ill adults: a comparison of tympanic and oral methods. Am. J. Crit. Care. 9:2000;254-261.
10. Craig S.C., Pittman P.R., Lewis T.E., Rossi C.A., Henchal E.A., Kuschner R.A.et al. An accelerated schedule for tick-borne encephalitis vaccine: the American Military experience in Bosnia. Am. J. Trop. Med. Hyg. 61:1999;874-878.
11. Harabacz I., Bock H., Jungst C., Klockmann U., Praus M., Weber R. A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens. Vaccine. 10:1992;145-150.